Cantor Fitzgerald Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $81.00

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target decreased by investment analysts at Cantor Fitzgerald from $163.00 to $81.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. Cantor Fitzgerald's price objective points to a potential upside of 117.11% from the company's current price.

Several other analysts also recently issued reports on SRPT. HC Wainwright cut their target price on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company began coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They issued an "overweight" rating and a $115.00 price target on the stock. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Finally, Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their target price for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $131.22.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $1.04 during midday trading on Wednesday, reaching $37.31. The company had a trading volume of 3,394,676 shares, compared to its average volume of 1,628,659. The firm has a market capitalization of $3.67 billion, a PE ratio of 29.84 and a beta of 0.85. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a fifty-two week low of $35.46 and a fifty-two week high of $173.25. The stock has a 50 day moving average price of $66.84 and a 200 day moving average price of $100.44.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter last year, the company earned $0.73 earnings per share. The business's revenue for the quarter was up 80.2% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Tidal Investments LLC increased its holdings in shares of Sarepta Therapeutics by 91.2% in the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock worth $704,000 after purchasing an additional 2,688 shares during the period. GAMMA Investing LLC increased its stake in Sarepta Therapeutics by 27.7% during the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 185 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after acquiring an additional 10,815 shares during the period. ORG Partners LLC grew its stake in shares of Sarepta Therapeutics by 17.6% in the fourth quarter. ORG Partners LLC now owns 2,000 shares of the biotechnology company's stock worth $243,000 after acquiring an additional 300 shares during the period. Finally, Harbor Capital Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 33.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,706 shares of the biotechnology company's stock worth $207,000 after buying an additional 427 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.